Longeveron (LGVN) Other Operating Expenses (2020 - 2024)
Longeveron (LGVN) posted quarterly Other Operating Expenses of -$100000.0 for Q3 2024, down 281.82% year-over-year from $55000.0 in Q4 2023, and little changed quarter-over-quarter from -$100000.0 in Q2 2024.
Longeveron (LGVN) Other Operating Expenses (2020 - 2024) Analysis & Trends
Longeveron's Other Operating Expenses history runs 5 years deep, the most recent figure standing at -$100000.0 for Q3 2024.
- In Q3 2024, Other Operating Expenses fell 281.82% year-over-year to -$100000.0; the TTM figure through Jun 2025 stood at -$100000.0 (down 122.22% YoY), while the FY2025 annual figure was -$97000.0, changed N/A from the prior year.
- Other Operating Expenses for Q3 2024 stood at -$100000.0, roughly flat from -$100000.0 in the prior quarter.
- The five-year high for Other Operating Expenses was $7.0 million in Q4 2021, with the low at -$1.4 million in Q2 2022.
- The 5-year median for Other Operating Expenses is $288000.0 (2020), against an average of $913437.5.
- The sharpest annual moves came in 2021 and 2024: Other Operating Expenses jumped 250.09% in 2021, then tumbled 281.82% in 2024.
- Longeveron's Other Operating Expenses stood at $2.5 million in 2020, then surged by 174.66% to $7.0 million in 2021, then sank by 95.91% to $285000.0 in 2022, then slumped by 80.7% to $55000.0 in 2023, then sank by 281.82% to -$100000.0 in 2024.
- Business Quant data shows LGVN's Other Operating Expenses at -$100000.0 in Q3 2024, -$100000.0 in Q2 2024, and $55000.0 in Q3 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -100,000.00 |
| Jun 30, 2024 | -100,000.00 |
| Sep 30, 2023 | 55,000.00 |
| Jun 30, 2023 | 80,000.00 |
| Dec 31, 2022 | 285,000.00 |
| Sep 30, 2022 | -57,000.00 |
| Jun 30, 2022 | -1.40 Mn |
| Mar 31, 2022 | 287,000.00 |
| Dec 31, 2021 | 6.96 Mn |
| Sep 30, 2021 | 2.05 Mn |
| Jun 30, 2021 | 1.96 Mn |
| Mar 31, 2021 | 550,000.00 |
| Dec 31, 2020 | 2.53 Mn |
| Sep 30, 2020 | 585,000.00 |
| Jun 30, 2020 | 642,000.00 |
| Mar 31, 2020 | 289,000.00 |